Oxandrolone
Oxandrolone is a small molecule pharmaceutical. Oxandrolone was first approved as Oxandrolone on 2006-12-01. It is used to treat emaciation and growth disorders in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxandrin | 2007-04-09 | |
| oxandrolone | ANDA | 2022-04-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| growth disorders | — | D006130 | — |
| emaciation | — | D004614 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wasting syndrome | D019282 | — | — | — | — | — | 1 | — | 1 |
| Cachexia | D002100 | HP_0004326 | R64 | — | — | — | 1 | — | 1 |
| Hiv wasting syndrome | D019247 | EFO_0007312 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 3 | 1 | — | — | 4 |
| Turner syndrome | D014424 | Orphanet_881 | Q96 | — | 2 | 1 | — | — | 3 |
| Gonadal dysgenesis | D006059 | — | — | — | 2 | 1 | — | — | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | — | 1 | 3 |
| Burns | D002056 | — | T30.0 | — | 2 | 2 | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | — | 1 |
| Weight loss | D015431 | HP_0001824 | — | — | — | 1 | — | — | 1 |
| Body weight changes | D001836 | — | — | — | — | 1 | — | — | 1 |
| Pressure ulcer | D003668 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | 1 | — | — | — | 2 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | 1 | — | — | — | 1 |
| Iron deficiencies | D000090463 | — | — | — | 1 | — | — | — | 1 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | — | — | — | 1 |
| Hypoplastic left heart syndrome | D018636 | — | Q23.4 | 1 | 1 | — | — | — | 1 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | 1 | — | — | — | 1 |
| Dwarfism | D004392 | HP_0003510 | E34.31 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Infant nutrition disorders | D007228 | — | — | 1 | — | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | — | — | — | — | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 1 | — | — | — | — | 1 |
| Fanconi syndrome | D005198 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular dystrophies | D009136 | HP_0003560 | G71.0 | — | — | — | — | 1 | 1 |
| Rotator cuff injuries | D000070636 | — | M75.1 | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxandrolone |
| INN | oxandrolone |
| Description | Oxandrolone is a 3-oxo steroid, an oxa-steroid, a 17beta-hydroxy steroid and an anabolic androgenic steroid. It has a role as an androgen and an anabolic agent. |
| Classification | Small molecule |
| Drug class | androgens; steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O |
Identifiers
| PDB | — |
| CAS-ID | 53-39-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200436 |
| ChEBI ID | 7820 |
| PubChem CID | 5878 |
| DrugBank | DB00621 |
| UNII ID | 7H6TM3CT4L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Oxandrolone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,305 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxandrin, Oxandrolone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
178 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use